Is BRCA2 p.Val159Met (c.475G>A) pathogenic?

BRCA2 p.Val159Met (c.475G>A) is classified Pathogenic/Likely pathogenic in BRCA2 (ClinVar, Multiple submitters, 12 submitters; last evaluated 2024-10-31). AlphaMissense: likely benign (0.1394); Absent from gnomAD v4.1; Associated with hereditary neoplastic syndrome.

What condition is associated with BRCA2 p.Val159Met (c.475G>A)?

BRCA2 p.Val159Met (c.475G>A) is associated with hereditary neoplastic syndrome, hereditary breast ovarian cancer syndrome, exocrine pancreatic carcinoma (ClinVar).

How common is BRCA2 p.Val159Met (c.475G>A) in the general population?

BRCA2 p.Val159Met (c.475G>A) is absent from gnomAD v4.1 (gnomAD).

What do computational predictors say about BRCA2 p.Val159Met (c.475G>A)?

AlphaMissense predicts likely benign (score 0.1394) — an in-silico prediction, not a clinical call.

BRCA2 p.Val159Met

c.475G>A · rs80358702 · VCV51711

Pathogenic/Likely pathogenic Multiple submitters

Classification

Pathogenic/Likely pathogenic

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 12 submitters

AlphaMissense

likely benign

0.1394 · ACMG-weighted

gnomAD v4.1

Absent

absent from gnomAD v4.1

Missense predictors

0/2 damaging

AlphaMissense, REVEL

Conditions

hereditary neoplastic syndrome

Computational evidence

Protein change
AlphaMissense	0.1394	likely benign ⚠ discordant with ClinVar
REVEL	0.162	moderately benign-leaning
⇒ AlphaMissense and REVEL both call this tolerated.
Splicing
SpliceAI	Δ0.75	donor loss · deltas
Pangolin	Δ0.76	loss · gain 0.00 · agrees with SpliceAI · independent
Constraint at this position
Conservation	phyloP 8.3	GERP 1.4, phastCons 1
Regional constraint	o/e 1.03	unconstrained · MANE · 47 kb · p 0.059 · regional, not allelic
Overall
CADD	33.0	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Cancer therapy — CIViC

Disease	Therapies	Level	Significance
Ovarian Cancer	Rucaparib	C	Sensitivity/Response

Variant & gene context

Gene: BRCA2
Protein: p.Val159Met
Coding: c.475G>A
MANE Select: NM_000059
dbSNP: rs80358702
Type: single nucleotide variant
Location: chr13:32326150 (GRCh38)
Gene constraint: LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)

Full BRCA2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

hereditary neoplastic syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Also linked: hereditary breast ovarian cancer syndrome exocrine pancreatic carcinoma breast-ovarian cancer, familial, susceptibility to, 2 hereditary breast carcinoma

Similar variants

BRCA2 p.Val159= Uncertain significance ★★ same residue
BRCA2 p.Val159Ala Uncertain significance ★★ ⚠ same residue
BRCA2 p.Val159Leu Conflicting classifications of pathogenicity ★ ⚠ same residue
BRCA2 p.Val159Glu Uncertain significance ⚠ same residue
BRCA2 c.316+1G>T Pathogenic ★★★ same condition
BRCA2 c.316+2T>C Pathogenic ★★★ same condition
BRCA2 c.316+5G>A Pathogenic ★★★ same condition
BRCA2 c.316+5G>C Pathogenic ★★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-val159met (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown